<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="keywords" content="" />
<meta name="description" content="" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<title>Neural Picks - Free AI Powered Stock Market Advice</title>
<link href="//fonts.googleapis.com/css?family=Abel|Arvo" rel="stylesheet" type="text/css" />
<link href="style.css" rel="stylesheet" type="text/css" media="screen" />
</head>
<body>
<div id="wrapper">
<div id="header">
<div id="logo">
<h1><a href="#">neural picks</a></h1>
</div>
</div>
<div id="about">
<h2 class="title">Updated on: 05/24/2021, 22:35:53</h2>
<p><img src="images/pics01.jpg" alt="" width="225" height="225" class="alignleft" /><strong>Disclaimer:</strong> This is a project for fun and none of the stock recommendations here should be executed using real money. I am not a professional stock advisor. All trading decisions and associated risks are your own, and I do not take responsibility for any losses.<br /><br /><strong>About:</strong> Stocks are ranked using Deep Learning according to performance on different quantitative and qualitative metrics. Stocks higher up on the list are predicted to have the highest returns over the next 3 weeks, but daily price swings can vary significantly. Forming a portfolio of multiple stocks can reduce daily risks.<br /><br /><strong>Contribute:</strong> Our mission is to further democratize finance by organizing high-quality publicly available information into actionable rankings. This information is free, however donations are highly appreciated at SegWit Bitcoin Wallet Address: bc1qxv7drjce5hx9l6eyht6ejtx2rex36an78fp82t</p>
<!-- AddToAny BEGIN -->
<div class="a2a_kit a2a_kit_size_32 a2a_default_style">
<a class="a2a_dd" href="https://www.addtoany.com/share"></a>
<a class="a2a_button_facebook"></a>
<a class="a2a_button_twitter"></a>
<a class="a2a_button_email"></a>
<a class="a2a_button_reddit"></a>
</div>
<script async src="https://static.addtoany.com/menu/page.js"></script>
<!-- AddToAny END --></div>
<div id="page">
<div id="content"><div class="post"><h2 class="title"><a href="#">VICI</a></h2><p class="meta">Rank #1 | $31.39 / share</p><div class="entry">       <p>VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.</p>       <ul>
       <li>Robinhood Adjusted Rating: 91.892%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 93.827%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $31.98 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 44.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ARCO</a></h2><p class="meta">Rank #2 | $6.22 / share</p><div class="entry">       <p>Arcos Dorados Holdings Inc. operates as a franchisee of McDonald's restaurants. It has the exclusive right to own, operate, and grant franchises of McDonald's restaurants in 20 countries and territories in Latin America and the Caribbean, including Argentina, Aruba, Brazil, Chile, Colombia, Costa Rica, Cura√ßao, Ecuador, French Guiana, Guadeloupe, Martinique, Mexico, Panama, Peru, Puerto Rico, Trinidad and Tobago, Uruguay, the U.S. Virgin Islands of St. Croix and St. Thomas, and Venezuela. As of December 31, 2019, it operated or franchised 2,293 restaurants. Arcos Dorados Holdings Inc. was founded in 2007 and is based in Montevideo, Uruguay.</p>       <ul>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 82.609%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>Fair Stock Price Estimate: $3.07 (Stock is Overvalued)</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MBIN</a></h2><p class="meta">Rank #3 | $42.37 / share</p><div class="entry">       <p>Merchants Bancorp (Indiana) is a bank holding company, which specializes in a multiple lines of business in banking and finance. The company is headquartered in Carmel, Indiana and currently employs 259 full-time employees. The Bank operate multiple lines of business with a focus on FHA multi-family housing and healthcare facility financing and servicing, mortgage warehouse financing, retail and correspondent residential mortgage banking, agricultural lending and traditional community banking. The Bank operates in three primary segments: Multi-family Mortgage Banking, Mortgage Warehousing, and Banking. The Multi-family Mortgage Banking segment originates and services government sponsored mortgages for multi-family and healthcare facilities. The Mortgage Warehousing segment funds agency eligible residential loans from origination or purchase to sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment provides a wide range of financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage and other consumer loan products.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $48.63 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 32.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MUR</a></h2><p class="meta">Rank #4 | $21.91 / share</p><div class="entry">       <p>Murphy Oil Corporation operates as an oil and natural gas exploration and production company in the United States, Canada, and internationally. It explores for and produces crude oil, natural gas, and natural gas liquids. The company was formerly known as Murphy Corporation and changed its name to Murphy Oil Corporation in 1964. Murphy Oil Corporation was incorporated in 1950 and is headquartered in El Dorado, Arkansas.</p>       <ul>
       <li>Robinhood Adjusted Rating: 26.667%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 43.307%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>Fair Stock Price Estimate: $23.93 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -28.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">CORT</a></h2><p class="meta">Rank #5 | $21.2 / share</p><div class="entry">       <p>Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>Social Media Sentiment: 37.991%</li>
       <li>Fair Stock Price Estimate: $21.97 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -4.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">GMAB</a></h2><p class="meta">Rank #6 | $39.49 / share</p><div class="entry">       <p>Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.</p>       <ul>
       <li>Robinhood Adjusted Rating: 69.388%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 83.396%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">TTD</a></h2><p class="meta">Rank #7 | $555.57 / share</p><div class="entry">       <p>The Trade Desk, Inc. operates as a technology company in the United States and internationally. The company operates a self-service cloud-based platform that allows buyers to create, manage, and optimize data-driven digital advertising campaigns in various advertising formats, including display, video, audio, native and social, and on various devices, such as computers, mobile devices, and connected TV. It also provides data and other value-added services, as well as platform features. The company serves advertising agencies and other service providers for advertisers. The Trade Desk, Inc. was founded in 2009 and is headquartered in Ventura, California.</p>       <ul>
       <li>Suggested By Multiple Sources</li>
       <li>Robinhood Adjusted Rating: 59.701%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 64.375%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 81.771%</li>
       <li>Recent Death Cross</li>
       <li>Fair Stock Price Estimate: $564.5 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -12.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">VRTX</a></h2><p class="meta">Rank #8 | $211.22 / share</p><div class="entry">       <p>Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.</p>       <ul>
       <li>Robinhood Adjusted Rating: 88.0%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 90.637%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 33.634%</li>
       <li>Fair Stock Price Estimate: $233.95 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -52.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FB</a></h2><p class="meta">Rank #9 | $324.63 / share</p><div class="entry">       <p>Facebook, Inc. develops products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and in-home devices worldwide. The company's products include Facebook that enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Instagram, a community for sharing photos, videos, and private messages; Messenger, a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices; and WhatsApp, a messaging application that is used by people and businesses to communicate in a private way. It also provides Oculus, a hardware, software, and developer ecosystem, which allows people to come together and connect with each other through its Oculus virtual reality products. Facebook, Inc. was founded in 2004 and is headquartered in Menlo Park, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 87.31%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 92.628%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: -86.169%</li>
       <li>Fair Stock Price Estimate: $330.73 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -80.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ATH</a></h2><p class="meta">Rank #10 | $62.7 / share</p><div class="entry">       <p>Athene Holding Ltd., a retirement services company, issues, reinsures, and acquires retirement savings products for individuals and institutions in the United States and Bermuda. The company provides annuity retirement solutions to its policyholders; and reinsures multi-year guaranteed annuities, fixed indexed annuities, traditional one-year guarantee fixed deferred annuities, immediate annuities, and institutional products. It also offers funding agreements and group annuities. The company was incorporated in 2008 and is headquartered in Pembroke, Bermuda.</p>       <ul>
       <li>Robinhood Adjusted Rating: 45.455%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 57.944%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $102.03 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FVRR</a></h2><p class="meta">Rank #11 | $189.56 / share</p><div class="entry">       <p>Fiverr International Ltd. operates an online marketplace worldwide. Its platform enables sellers to sell their services and buyers to buy them. The company's platform includes approximately 300 categories in eight verticals, including graphic and design, digital marketing, writing and translation, video and animation, music and audio, programming and technology, business, and lifestyle. It also offer And.Co, a platform for online back office service to assist freelancers with invoicing, contracts and task management; Fiverr Learn, an online learning platform with original course content in categories such as graphic design, branding, digital marketing, and copywriting; and ClearVoice, a subscription based content marketing platform for medium to large businesses. Its buyers include businesses of various sizes, as well as sellers comprise a group of freelancers and small businesses. The company was founded in 2010 and is headquartered in Tel Aviv, Israel.</p>       <ul>
       <li>Robinhood Adjusted Rating: 68.571%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 82.946%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Social Media Sentiment: -4.995%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">IMAB</a></h2><p class="meta">Rank #12 | $69.78 / share</p><div class="entry">       <p>I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. I-Mab has a collaboration agreement with AbbVie Inc. for the development and commercialization of TJC4, an anti-CD47 monoclonal antibody for the treatment of multiple cancers. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.</p>       <ul>
       <li>Robinhood Adjusted Rating: 100.0%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 96.774%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">AMZN</a></h2><p class="meta">Rank #13 | $3244.99 / share</p><div class="entry">       <p>Amazon.com, Inc. engages in the retail sale of consumer products and subscriptions in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It sells merchandise and content purchased for resale from third-party sellers through physical and online stores. The company also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Rings, and Echo and other devices; provides Kindle Direct Publishing, an online service that allows independent authors and publishers to make their books available in the Kindle Store; and develops and produces media content. In addition, it offers programs that enable sellers to sell their products on its Websites, as well as its stores; and programs that allow authors, musicians, filmmakers, skill and app developers, and others to publish and sell content. Further, the company provides compute, storage, database, and other AWS services, as well as fulfillment, advertising, publishing, and digital content subscriptions. Additionally, it offers Amazon Prime, a membership program, which provides free shipping of various items; access to streaming of movies and TV episodes; and other services. The company also operates in the food delivery business in Bengaluru, India. It serves consumers, sellers, developers, enterprises, and content creators. The company also has utility-scale solar projects in China, Australia, and the United States. Amazon.com, Inc. was founded in 1994 and is headquartered in Seattle, Washington.</p>       <ul>
       <li>Robinhood Adjusted Rating: 96.97%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 96.907%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 62.31%</li>
       <li>Social Media Sentiment: 4.995%</li>
       <li>Recent Golden Cross</li>
       <li>Fair Stock Price Estimate: $3327.58 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -100.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ABNB</a></h2><p class="meta">Rank #14 | $135.91 / share</p><div class="entry">       <p>Airbnb, Inc. operates a platform for stays and experiences to guests worldwide. The company's marketplace model connects hosts and guests online or through mobile devices to book spaces and experiences. It primarily offers private rooms and luxury villas. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 40.0%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 57.447%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 59.31%</li>
       <li>Social Media Sentiment: 69.102%</li>
       <li>Insider Trading Transactions Rating: -20.0%</li>
       </ul>
</div></div></div>
</div>
</div>
<div id="footer">
<p>&copy; Jonathan Davies. All rights reserved. Design by <a href="http://templated.co" rel="nofollow">TEMPLATED</a>.</p>
</div>
</body>
</html>